| Date | Title | Description |
| 25.11.2025 | Key leadership roles filled across multiple startups |
Since the beginning of November this year, Maximilian Eils has taken the helm at Spectroplast as Chief Executive Officer, the startup enabling for the first time the direct fabrication of silicone products. Maximilian brings deep expertise... |
| 12.11.2025 | Alentis Strengthens Management Team with Key Appointments | Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing first-in-class therapies targeting claudin-1 for a range of fibrosis and oncology indications, today announced the appointment of Bryan Yoon as General Coun... |
| 17.10.2025 | New leadership drives growth in biotech and AI startups |
Mark Pruzanski, a renowned physician entrepreneur is the newly appointed Chief Executive Officer of Alentis, a clinical-stage biotechnology company pioneering first-in-class antibodies and antibody-drug conjugates (ADCs) targeting claudin-... |
| 20.11.2024 | Alentis Therapeutics: $181.4 Million (Series D) Raised For Advancing Clinical Development Of Anti-Claudin-1 ADCs | Alentis Therapeutics – a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis – announced that it has raised $181.4 million in Series D financing, supported by a syndicate of t... |
| 20.11.2024 | FDA approval and a key partnership to accelerate drug development |
The Fast Track Designation from the U.S. Food and Drug Administration (FDA) is aimed at accelerating the development and review process for drugs that address unmet medical needs, offering benefits like priority review, increased interacti... |
| 13.11.2024 | Alentis Therapeutics Secures $181.4 Million to Pioneer Cancer Treatments | In a bold move to reshape cancer treatment, Alentis Therapeutics has successfully raised $181.4 million in an oversubscribed Series D funding round. This infusion of capital, led by OrbiMed and co-led by Novo Holdings and Jeito Capital, sig... |
| 13.11.2024 | Alentis Therapeutics: $181.4 Million (Series D) Raised To Develop Treatments For Claudin-1 Tumors | Alentis Therapeutics – a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis – announced that it has raised $181.4 million in Series D funding, supported by a syndicate of top... |
| 12.11.2024 | Alentis Therapeutics raises $181.4 million in oversubscribed series D round | Normal 0 false false false EN-GB X-NONE AR-SA
Besides OrbiMed, Novo Holdings and Jeito Capital, Alentis Therapeutics’ series D round saw the participation of new investors Frazier Life Sciences, Longitude Capital, Catalio Capital, Piper Hea... |
| 12.11.2024 | Jeito Capital co-leads €164.5 million ($181.4 million) oversubscribed Series D financing in Alentis Therapeutics to advance clinical development of Anti-Claudin-1 ADCs in solid tumors | Jeito Capital co-leads €164.5 million1 ($181.4 million) oversubscribed Series D financing in Alentis Therapeutics to advance clinical development of
Anti-Claudin-1 (CLDN1) ADCs in solid tumors
Building on its co-lead investments in Alentis ... |
| 18.10.2024 | Swiss Startups Soar: A New Era of Innovation and Investment | Switzerland is a land of precision, chocolate, and now, a burgeoning startup ecosystem. The Swiss startup scene is buzzing with energy, creativity, and ambition. Recent awards and funding announcements reveal a landscape ripe for innovation... |
| 17.10.2024 | Generous cash prizes awarded to Swiss startups |
Ananya Bala, founder of dancing shoes startup marleys, has been selected as the 2024 winner of the IMD MBA Venture Award, securing 100,000 CHF in funding, as well as mentorship and strategic guidance from a panel of successful IMD entrepre... |
| 07.10.2024 | FDA approvals and clinical advancements propel life sciences startups forward |
Alentis Therapeutics, a clinical-stage biotech company focused on developing treatments for cancer and fibrosis, has received FDA clearance for an Investigational New Drug (IND) application for ALE.P02, a novel anti-CLDN1 ADC targeting squ... |
| 06.09.2024 | Navigating Change: The Evolution of Leadership in Startups | The startup landscape is a dynamic ecosystem. It thrives on innovation, agility, and leadership. Recent shifts in executive roles across various companies highlight this evolution. New leaders bring fresh perspectives, driving growth and ad... |
| 06.09.2024 | Strategic and leadership changes in the Startup landscape |
Simone Severini has joined Modulos AG, a leader in developing AI products and services in a new regulated environment, as Chief Revenue Officer and as the company’s third co-founder, joining Kevin Schawinski and Ce Zhang. Severini has been... |
| 13.07.2023 | Startups gather Board members’ expertise | |
| 15.06.2023 | Alentis gets FDA green light to enter the oncology sector | |
| 10.05.2023 | Biotech startups turn gear into Phase 2 clinical trials | |
| 28.04.2023 | Swiss Accelerator: Innosuisse supports 53 companies with CHF112 million | |
| 14.04.2023 | Switzerland-based Alentis Therapeutics raises USD 105 million in Series C | Basel, Switzerland-based clinical-stage biotech developing breakthrough treatments for organ fibrosis and Claudin-1 (CLDN1) positive tumours, Alentis Therapeutics, raised USD 105 million in Series C. The round took place on April 13, 2023. ... |
| 13.04.2023 | Alentis Therapeutics closes $105 million Series C funding to advance transformational medicines for Claudin-1 | April 13, 2023 |
| 13.04.2023 | Alentis Therapeutics Lands $105M for Clinical Trials in Fibrosis and Cancer | Alentis Therapeutics, a biotech pursuing a novel target as a way of treating fibrosis and cancer, has raised $105 million for clinical trials in both.
The focus of Alentis’s drug research is Claudin 1 (CLDN1), a member of the tight junction... |
| 13.04.2023 | Alentis Therapeutics Raises US$105M in Series C Funding | Alentis Therapeutics, a Basel, Switzerland-based clinical-stage biotech developing breakthrough treatments for organ fibrosis and Claudin-1 (CLDN1) positive tumors, raised US$105m in Series C financing.
The round was led by Jeito Capital wi... |
| 13.04.2023 | Alentis Therapeutics closes USD 105 million Series C round | |
| 13.04.2023 | Alentis secures USD 105 million to boost development of its cancer-treatment platform | Alentis secures USD 105 million to boost development of its cancer-treatment platform 13.04.2023 09:45, Morgane Ghilardi linkedIn facebook twitter instagram youtube -->
The biotech startup Alentis Therapeutics announced today that it clo... |
| 13.04.2023 | Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis | - |
| 13.04.2023 | Alentis rides in zolbetuximab's slipstream to secure $105M series C for anti-fibrotic ambitions | The string of recent clinical successes for the antibody zolbetuximab has not only been welcome good news at AstraZeneca and Astellas, it has also buoyed biotechs working on their own Claudin-targeting therapies.
Chief among them is Alentis... |
| 10.01.2023 | Alentis reports positive results of Phase 1 clinical trial | |
| 21.07.2022 | Ten Biotech startups brace for Boston | |
| 16.06.2021 | USD67 million for Alentis Therapeutics | Alongside Morningside Venture Investments, Jeito Capital and Series A investors BioMed Partners, BB Pureos Bioventures, Bpifrance through its InnoBio 2 fund, High-Tech Gründerfonds and Schroders Capital joined Alentis’ financing round.
&quo... |
| 16.06.2021 | USD67 million for Alentis Therapeutics | |
| 15.06.2021 | Alentis Therapeutics Raises $67M in Series B Financing | Alentis Therapeutics, a Basel, Switzerland biotech developing treatments for fibrotic diseases, raised USD67 (CHF60)m in Series B financing round.
The round was led by Morningside Venture Investments, joined by Jeito Capital and Series A in... |
| 15.06.2021 | Jeito Capital becomes key investor in Alentis Therapeutics as part of $67 million Series B financing round | Jeito Capital becomes key investor in Alentis Therapeutics as part of $67 million Series B financing round
Jeito Capital selects Alentis Therapeutics as its fifth investment since launching the fundAlentis is focused on the development of b... |
| 15.06.2021 | Alentis Therapeutics : Raises USD 67 Million in Series B Financing | Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, today announced that it has raised USD67 (CHF60) million in a Series B financing round. The funding will be used primarily for proof-of-concep... |
| 15.01.2021 | Five deeptech solutions awarded worldwide | Futurae: Endeavor Scale-up Program, Greece
Zurich based Futurae is a cybersecurity company providing a robust two-factor authentication suite that offers a high-security level to businesses and individuals to protect their accounts and sens... |
| 15.01.2021 | Five deeptech solutions awarded worldwide | |
| 31.07.2020 | Executives with business acumen to lead startups | |
| 31.07.2020 | Executives with business acumen to lead startups | From its headquarters Zurich, smartwatcher provides safety services through its technology a platform consisting of personal safety apps for smartwatches and smartphones complemented by personal safety alarm smartwatches. With a firm footho... |
| 01.05.2019 | Daily funding roundup - May 1st, 2019 | Allganize landed $3.4M; Vault Platform closed $4.2M; Pana raised $10M: DivvyCloud secured $20M
Allganize: Allganize provides the best-in-class Natural Language Understanding API and conversational AI for enterprises. Allganize has raised $3... |
| 01.05.2019 | Alentis Therapeutics Closes CHF12.5M Series A Financing | Alentis Therapeutics, a Basel, Switzerland – based biotech company developing novel therapeutics in advanced liver disease and cancer, closed a CHF 12.5m (€11.1m; USD12.5m) Series A financing.
The round was co-led by BioMedPartners and BB P... |
| 30.04.2019 | ALENTIS Therapeutics raises CHF 12.5m in a Series A | |
| - | Alentis Therapeutics | “Alentis Therapeutics – NOVEL MECHANISMS TO TREAT ADVANCED LIVER DISEASES” |
| - | ALENTIS Therapeutics launches, raising CHF 12.5m in a Series A to develop novel therapeutics in advanced liver disease and cancer | ALENTIS Therapeutics (“ALENTIS”), a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer, announced today the completion of a Series A financing of CHF 12.5million (Euro 11.1m; USD 12.5m). The Swis... |
| - | Alentis Therapeutics | “THE CLAUDIN-1 COMPANY Treat cancer and reverse fibrosis We are a clinical-stage biotech company with a mission to treat cancer and reverse fibrosis. To this end, we are rapidly advancing our pipeline of anti-Claudin-1 monoclonal antibodies... |
| - | Alentis Therapeutics Raises USD 67 Million in Series B Financing | June 15, 2021 |
| - | Claudin-1 (CLDN1) Company Alentis Therapeutics Raises $105 Million | Alentis Therapeutics – the Claudin-1 (CLDN1) company – is a clinical-stage biotech developing breakthrough treatments for organ fibrosis and CLDN1 positive tumors. And the company recently announced $105 million in Series C financing. This ... |
